Electroencephalography Based Neurofeedback in Chronic Neuropathic Pain
Recruitment status was Not yet recruiting
Chronic neuropathic pain is a global health concern, affecting millions of patients worldwide. It is often extremely debilitating and poses a diagnostic and therapeutic challenge. The current mainstay of treatment is pharmacotherapy consisting of powerful analgesics combined with different classes of drugs that change nerve cell membrane properties. However, response to pharmacotherapy is often poor and mandates interventional strategies. Among the latest and most promising interventional strategies is the use of neurostimulation to targeted brain areas, specifically the primary motor cortex . Motor cortex stimulation , both invasive and noninvasive (using megnetic or electical stimulation), has emerged as a highly beneficial treatment, and is currently included in different professional guidelines for the treatment of medically refractory neuropathic pain.
A possible alternative way to achieve stimulation of the motor cortex is by using EEG based neurofeedback. This design, which is actually a Brain Computer Interface (BCI) enables the patient to voluntarily modulate the activity of a circumscribed brain area after a few training sessions. While EEG based neurofeedfback is decades old, it has never been tested in neuropathic pain patients.
This experiment is intended to compare both the clinical effects and the brain correlates of a BCI based self modulation of M1 activity and of exogenous magnetic brain stimulation in a population of patients suffering from chronic neuropathic pain of an upper limb. 15 such patients will receive a course of 10 daily magnetic stimulation sessions with stimulation of M1 as described in the literature. A further 30 patients will be divided into two groups: 15 will perform a course of 10 real BCI neurofeedback sessions modulating motor cortex activity and 15 will perform a course of 10 sham neurofeedback sessions. The participants' baseline chronic pain levels and their response to acute painful stimuli will be clinically evaluated before and after the course, and for an additional 1 month. Furthermore, before and after the course patients will be scanned using functional MRI during rest (baseline pain levels) and during acute pain. These scans are performed both to describe the neural correlates of the analgesia induced by motor cortex magnetic stimulation , and to compare the observed networks to the network effect of a BCI neurofeedback modulation of motor cortex activity.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
|Official Title:||Voluntary Modulation of M1 Motor Cortex Activity Using EEG Neurofeedback for the Treatment of Resistant Chronic Neuropathic Pain - a Clinical and fMRI Study|
- daily pain levels [ Time Frame: during three weeks of treatments ] [ Designated as safety issue: No ]daily pain levels will be assessed using a visual assessment score (VAS) during the treament phase (lasting aproximately 3 weeks)
- Daily pain measures for one month following the last session [ Time Frame: one month following the last treatment session ] [ Designated as safety issue: No ]Daily pain scores based on the VAS (visual-analogue scale) system will be assessed for a further one month following the last treatment session.
|Study Start Date:||April 2012|
|Estimated Study Completion Date:||April 2014|
|Estimated Primary Completion Date:||April 2013 (Final data collection date for primary outcome measure)|
Active Comparator: Real EEG-NF
10 EEG based neurofeedback sessions modulating the activity of the primary motor cortex
EEG neurofeedback based on the primary motor cortex
Sham Comparator: Sham EEG-NF
10 sessions of Sham EEG_NF of the motor cortex area
Other: Sham neurofeedback
Sham EEG neurofeedback
Active Comparator: Transcrainal Magnetic Stimulation
10 dailt TMS stimulation sessions of M1
Transcranial magentic stimulation of the motor cortex. Device Details : Model is Magstim TMS Rapid. Manufacturer : MAGSTIM CO LTD. Spring Gardens, Whitland, Carmarthenshire, Wales, U.K., SA34 0HR
Please refer to this study by its ClinicalTrials.gov identifier: NCT01560039
|Contact: Haggai Sharon, MDfirstname.lastname@example.org|
|Functional Brain Center, Sourasky Medical Center||Not yet recruiting|
|Tel Aviv, Israel|
|Study Director:||Talma Hendler, MD, PhD||Sourasky Medical Center|